Point-of-Care Testing for Women Health Market
完整報告名稱與涵蓋範圍
Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Müllerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, β-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032
報告摘要
Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Müllerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, β-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032
Market Overview
The global Point-of-Care testing for women’s health market was valued at USD 16,627.22 million in 2023 and is projected to reach USD 28,768.16 million by 2032, growing at a CAGR of 6.26%. Point-of-Care Testing (POCT) for women's health is a concept that refers to the use of rapid and easy-to-perform diagnostic tools close to or at the patient's site, without the need for traditional laboratory tests. Such tests focus on the main health aspects of fertility, pregnancy, infections, and gynecological conditions, thus allowing quicker clinical decisions to be made. Since these testing solutions deliver both accuracy and convenience, POCT becomes instrumental in early diagnosis and the overall women's health care outcomes.
The high prevalence of infectious diseases among women is significantly fueling the growth of the global point-of-care (POC) testing market for women’s health by driving demand for rapid and accessible diagnostic solutions. Conditions such as sexually transmitted infections (STIs), urinary tract infections (UTIs), and HPV require timely detection for effective treatment, making POC tests indispensable.
Major Company Development
Swiss Precision Diagnostics GmbH (SPD) continues to strengthen its leadership in women’s health diagnostics with impactful product and technology innovations. In August 2023, SPD introduced the Clearblue Menopause Stage Indicator, the first-ever at-home product designed to help women understand their likely menopause stage. This groundbreaking device combines urine FSH measurements with age and menstrual cycle history, offering women clarity and control over their health journey. Earlier, in August 2020, SPD adopted the Matrix Gemini Laboratory Information Management System (LIMS) to enhance pregnancy-related studies. This advanced digital platform improved the efficiency of volunteer sample collection, laboratory testing, and biobank management. Collectively, these developments highlight SPD’s commitment to pioneering accessible, reliable, and technology-driven women’s health solutions.
Major Players
Key players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.
Report Attribute Details
Market Size 2023 USD 16,627.22 Million
Market Size 2032 USD 28,768.16 Million
CAGR (2024-2032) 6.26%
Base Year 2023
Market Forecast Period 2024-2032
Historical Data 2019-2024
Market Segmentations CAGR (2024-2032)
By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.
By Age: Adolescent – 8.18%, Adult – 6.20%.
By Sample Type: Serum - 5.27%, Plasma - 4.30%.
By Test Type: Testosterone Test – 4.12%, Estradiol Test – 3.53%.
By Technology: Colloidal Gold Lateral Flow Assays – 7.19%, Fluorescence Immunoassays – 5.46%.
By Application: Gestational Diabetes – 5.34%, Vaginal Infection – 4.08%.
By Distribution Channel: Offline – 5.49%, Online – 7.35%.
By End User: Hospitals – 5.42 %, Diagnostic Laboratories – 6.96%.
Regional Insights
North America holds the POCT for women’s health market, supported by the advanced healthcare infrastructure and high adoption of rapid diagnostic solutions. The US dominated the North American women’s point-of-care testing market in 2023 with USD 5,735.44 million, far ahead of Canada (USD 889.72 million) and Mexico (USD 426.32 million).
Europe is experiencing substantial growth due to the adoption of innovative diagnostic tools and the emphasis on preventive healthcare. Germany led Europe’s women’s point-of-care testing market in 2023 with USD 1,220.06 million, followed by the UK at USD 906.19 million and France at USD 775.11 million. The market growth is being supported by such factors as government programs and the rising popularity of home-based diagnostics in the countries with the largest economies.
Asia-Pacific is the fastest-growing market, fueled by rising population, increasing healthcare reforms, and growing awareness of women’s health. China led the Asia-Pacific market for women’s point-of-care testing in 2023 with USD 751.65 million, followed by India (USD 634.81 million) and Japan (USD 607.31 million). Rapid adoption of POCT in rural areas, where laboratory access is limited, strengthens market penetration.
The Rest of the World market is gaining traction as POCT becomes a critical solution in regions with limited healthcare infrastructure. Strategic collaborations introducing low-cost, portable devices are expanding the market reach significantly.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 31
2 MARKET INTRODUCTION 33
2.1 DEFINITION 33
2.2 SCOPE OF THE STUDY 33
2.3 RESEARCH OBJECTIVE 33
2.4 MARKET STRUCTURE 34
3 RESEARCH METHODOLOGY 35
3.1 OVERVIEW 35
3.2 DATA FLOW 37
3.2.1 DATA MINING PROCESS 37
3.3 PURCHASED DATABASE: 38
3.4 SECONDARY SOURCES: 39
3.4.1 SECONDARY RESEARCH DATA FLOW: 40
3.5 PRIMARY RESEARCH: 41
3.5.1 PRIMARY RESEARCH DATA FLOW: 42
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 43
3.6.1 REVENUE ANALYSIS APPROACH 43
3.7 DATA FORECASTING 44
3.7.1 DATA FORECASTING TYPE 44
3.8 DATA MODELING 45
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 45
3.8.2 DATA MODELING: 46
3.9 TEAMS AND ANALYST CONTRIBUTION 48
4 MARKET DYNAMICS 50
4.1 INTRODUCTION 50
4.2 DRIVERS 51
4.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES IN WOMEN 51
4.2.2 INCREASING CASES OF INFERTILITY AMONG WOMEN 51
4.2.3 GROWING STRATEGIC INITIATIVES ASSOCIATED WITH THE POINT-OF-CARE TESTING FOR WOMEN HEALTH 52
4.3 RESTRAINTS 53
4.3.1 INACCURACY OF POINT OF CARE DIAGNOSTIC TESTS 53
4.4 OPPORTUNITY 54
4.4.1 RISING AWARENESS AND HEALTH INITIATIVES 54
4.4.2 HIGH COST OF DIAGNOSTIC IMAGING SYSTEMS AND PROCEDURES 55
5 MARKET FACTOR ANALYSIS 56
5.1 PORTER'S FIVE FORCES MODEL 56
5.1.1 THREAT OF NEW ENTRANTS 56
5.1.2 BARGAINING POWER OF SUPPLIERS 57
5.1.3 THREAT OF SUBSTITUTES 57
5.1.4 BARGAINING POWER OF BUYERS 57
5.1.5 INTENSITY OF RIVALRY 57
5.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET 58
5.3 CONSUMER PREFERENCE ANALYSIS 59
5.4 REGULATORY LANDSCAPE AND ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS 60
5.4.1 REGULATORY LANDSCAPE 60
5.4.2 ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS 61
5.5 EFFECTS OF TRANSITION OF IVDD TO IVDR ON GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET 62
6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT 65
6.1 OVERVIEW 65
6.2 INSTRUMENTS/DEVICES 67
6.3 REAGENTS & KITS 68
6.4 CONSUMABLES 68
7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE 69
7.1 OVERVIEW 69
7.2 ADOLESCENT 71
7.3 ADULT 72
7.4 GERIATRIC 72
8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE 73
8.1 OVERVIEW 73
8.2 SERUM 75
8.3 PLASMA 76
8.4 WHOLE BLOOD 76
8.5 URINE 77
8.6 OTHERS 77
9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 78
9.1 OVERVIEW 78
9.2 TESTOSTERONE TEST 81
9.3 ESTRADIOL TEST 81
9.4 ANTI-MÜLLERIAN HORMONE TEST 82
9.5 PROLACTIN TEST 82
9.6 PROGESTERONE TEST 83
9.7 FOLLICLE-STIMULATING HORMONE TEST 83
9.8 LUTEINIZING HORMONE TEST 84
9.9 Β-HCG TEST 84
9.10 OTHERS 85
10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 86
10.1 OVERVIEW 86
10.2 COLLOIDAL GOLD LATERAL FLOW ASSAYS 88
10.3 FLUORESCENCE IMMUNOASSAYS 89
10.4 LAB-ON-A-CHIP 89
10.5 OTHERS 90
11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION 91
11.1 OVERVIEW 91
11.2 GESTATIONAL DIABETES 95
11.3 VAGINAL INFECTION 96
11.4 URINARY TRACT INFECTION 96
11.5 CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS 97
11.6 HEMOGLOBIN DEFICIENCY 97
11.7 BREAST CANCER 98
11.8 THYROID DISEASE 98
11.9 SEXUALLY TRANSMITTED INFECTIONS 99
11.9.1 CHLAMYDIA 100
11.9.2 GONORRHEA 100
11.9.3 HIV 101
11.9.4 SYPHILIS 101
11.9.5 OTHERS 102
11.10 FERTILITY CONDITIONS 102
11.10.1 POLYCYSTIC OVARY SYNDROME 103
11.10.2 OVULATION DISORDERS 104
11.10.3 OTHERS 104
11.11 PREGNANCY TESTING 105
11.12 OTHERS 105
12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL 106
12.1 OVERVIEW 106
12.2 OFFLINE 108
12.2.1 HOSPITAL PHARMACIES 109
12.2.2 RETAIL PHARMACIES 110
12.2.3 HYPERMARKET/SUPERMARKET 110
12.3 ONLINE 111
12.3.1 E-COMMERCE PLATFORMS 112
12.3.2 ONLINE PHARMACIES 112
13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER 113
13.1 OVERVIEW 113
13.2 HOSPITALS 115
13.3 DIAGNOSTIC LABORATORIES 116
13.4 HOME SETTINGS 116
13.5 OTHERS 117
14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION 118
14.1 OVERVIEW 118
14.2 NORTH AMERICA 120
14.2.1 US 128
14.2.2 CANADA 132
14.2.3 MEXICO 137
14.3 EUROPE 143
14.3.1 GERMANY 151
14.3.2 FRANCE 155
14.3.3 UK 160
14.3.4 ITALY 165
14.3.5 SPAIN 170
14.3.6 REST OF EUROPE 175
14.4 ASIA-PACIFIC 181
14.4.1 CHINA 189
14.4.2 INDIA 194
14.4.3 JAPAN 199
14.4.4 AUSTRALIA 204
14.4.5 SOUTH KOREA 209
14.4.6 SOUTH EAST ASIA 214
14.4.6.1 MALAYSIA 220
14.4.6.2 SINGAPORE 226
14.4.6.3 THAILAND 231
14.4.6.4 VIETNAM 236
14.4.6.5 PHILIPPINES 241
14.4.6.6 INDONESIA 246
14.4.6.7 REST OF SOUTH EAST ASIA 251
14.4.7 REST OF ASIA-PACIFIC 256
14.5 REST OF THE WORLD 262
14.5.1 MIDDLE EAST & AFRICA 269
14.5.2 SOUTH AMERICA 275
14.5.2.1 BRAZIL 281
14.5.2.2 ARGENTINA 286
14.5.2.3 CHILE 291
14.5.2.4 REST OF SOUTH AMERICA 296
15 COMPETITIVE LANDSCAPE 302
15.1 INTRODUCTION 302
15.2 MARKET SHARE ANALYSIS, 2023 302
15.3 COMPETITOR DASHBOARD 303
15.4 PUBLIC PLAYERS STOCK SUMMARY 304
15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 304
15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 304
15.6.1 PRODUCT LAUNCH 304
15.6.2 TECHNOLOGY LAUNCH 305
15.6.3 AQUISITION 305
15.6.4 PRODUCT RECOGNITION 305
16 COMPANY PROFILES 306
16.1 SWISS PRECISION DIAGNOSTICS GMBH - CLEARBLUE 306
16.1.1 COMPANY OVERVIEW 306
16.1.2 PRODUCTION OVERVIEW 307
16.1.3 FINANCIAL OVERVIEW 307
16.1.4 PRODUCTS OFFERED 307
16.1.5 DISTRIBUTION CHANNEL 307
16.1.6 PRICE ANALYSIS 308
16.1.7 PROMOTION STRATEGY 309
16.1.8 TECHNOLOGY ANALYSIS 309
16.1.9 KEY DEVELOPMENTS 310
16.1.10 SWOT ANALYSIS 311
16.1.11 KEY STRATEGIES 311
16.2 WONDFO 312
16.2.1 COMPANY OVERVIEW 312
16.2.2 PRODUCTION OVERVIEW 313
16.2.3 FINANCIAL OVERVIEW 313
16.2.4 PRODUCTS OFFERED 313
16.2.5 TECHNOLOGY 313
16.2.6 KEY DEVELOPMENTS 314
16.2.7 SWOT ANALYSIS 316
16.2.8 KEY STRATEGIES 316
16.3 CHURCH & DWIGHT CO., INC. - FIRST RESPONSE 317
16.3.1 COMPANY OVERVIEW 317
16.3.2 PRODUCTION OVERVIEW 318
16.3.3 FINANCIAL OVERVIEW 319
16.3.4 PRODUCTS OFFERED 319
16.3.5 DISTRIBUTION CHANNEL 320
16.3.6 PRICE ANALYSIS 320
16.3.7 PROMOTION 320
16.3.8 TECHNOLOGY ANALYSIS 320
16.3.9 KEY DEVELOPMENTS 321
16.3.10 SWOT ANALYSIS 321
16.3.11 KEY STRATEGIES 322
16.4 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD. 323
16.4.1 COMPANY OVERVIEW 323
16.4.2 PRODUCTION OVERVIEW 323
16.4.3 FINANCIAL OVERVIEW 323
16.4.4 PRODUCT OFFERED 324
16.4.5 TECHNOLOGY ANALYSIS 324
16.4.6 KEY DEVELOPMENTS 325
16.4.7 KEY STRATEGIES 325
16.5 W.H.P.M., INC. 326
16.5.1 COMPANY OVERVIEW 326
16.5.2 PRODCUTION OVERVIEW 326
16.5.3 FINANCIAL OVERVIEW 326
16.5.4 PRODUCTS OFFERED 327
16.5.5 TECHNOLOGY ANALYSIS 327
16.5.6 KEY DEVELOPMENTS 327
16.5.7 KEY STRATEGIES 328
16.6 SEKISUI DIAGNOSTICS 329
16.6.1 COMPANY OVERVIEW 329
16.6.2 PRODUCTION OVERVIEW 329
16.6.3 FINANCIAL OVERVIEW 329
16.6.4 PRODUCTS OFFERED 330
16.6.5 TECHNOLOGY ANALYSIS 330
16.6.6 KEY DEVELOPMENTS 331
16.6.7 SWOT ANALYSIS 331
16.6.8 KEY STRATEGIES 332
16.7 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD 333
16.7.1 COMPANY OVERVIEW 333
16.7.2 FINANCIAL OVERVIEW 333
16.7.3 PRODUCTS OFFERED 333
16.7.4 TECHNOLOGY ANALYSIS 334
16.7.5 KEY DEVELOPMENTS 334
16.7.6 KEY STRATEGIES 334
16.8 YANGZHOU VIOMED 335
16.8.1 COMPANY OVERVIEW 335
16.8.2 PRODUCTION OVERVIEW 335
16.8.3 FINANCIAL OVERVIEW 335
16.8.4 PRODUCTS OFFERED 335
16.8.5 TECHNOLOGY ANALYSIS 336
16.8.6 KEY DEVELOPMENTS 336
16.8.7 KEY STRATEGIES 336
16.9 COFOE MEDICAL TECHNOLOGY CO., LTD. 337
16.9.1 COMPANY OVERVIEW 337
16.9.2 PRODUCTION OVERVIEW 337
16.9.3 FINANCIAL OVERVIEW 337
16.9.4 PRODUCTS OFFERED 338
16.9.5 KEY DEVELOPMENTS 338
16.9.6 TECHNOLOGY ANALYSIS 338
16.9.7 SWOT ANALYSIS 339
16.9.8 KEY STRATEGIES 339
16.10 CHUNGDO PHARM CO., LTD. 340
16.10.1 COMPANY OVERVIEW 340
16.10.2 PRODUCTION OVERVIEW 340
16.10.3 FINANCIAL OVERVIEW 341
16.10.4 PROUDCTS OFFERED 341
16.10.5 TECHNOLOGY ANALYSIS 341
16.10.6 KEY DEVELOPMENTS 341
16.10.7 KEY STRATEGIES 341
16.11 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. 342
16.11.1 COMPANY OVERVIEW 342
16.11.2 PRODUCTION OVERVIEW 342
16.11.3 FINANCIAL OVERVIEW 342
16.11.4 PRODUCTS OFFERED 343
16.11.5 TECHNOLOGY ANALYSIS 344
16.11.6 KEY DEVELOPMENTS 344
16.11.7 SWOT ANALYSIS 345
16.11.8 KEY STRATEGIES 345
16.12 EASY HEALTHCARE CORPORATION 346
16.12.1 COMPANY OVERVIEW 346
16.12.2 PRODUCTION OVERVIEW 346
16.12.3 FINANCIAL OVERVIEW 346
16.12.4 PRODUCTS OFFERED 346
16.12.5 TECHNOLOGY 347
16.12.6 KEY DEVELOPMENTS 348
16.12.7 KEY STRATEGIES 348
17 DATA CITATIONS 349
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 46
TABLE 2 DIFFERENCE BETWEEN IVDD & IVDR 62
TABLE 3 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 66
TABLE 4 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR INSTRUMENTS/DEVICES, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 5 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR REAGENTS & KITS, BY REGION, 2019–2032 (USD MILLION) 68
TABLE 6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CONSUMABLES, BY REGION, 2019–2032 (USD MILLION) 68
TABLE 7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 70
TABLE 8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ADOLESCENT, BY REGION, 2019–2032 (USD MILLION) 71
TABLE 9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ADULT, BY REGION, 2019–2032 (USD MILLION) 72
TABLE 10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GERIATRIC, BY REGION, 2019–2032 (USD MILLION) 72
TABLE 11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 74
TABLE 12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SERUM, BY REGION, 2019–2032 (USD MILLION) 75
TABLE 13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PLASMA, BY REGION, 2019–2032 (USD MILLION) 76
TABLE 14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR WHOLE BLOOD, BY REGION, 2019–2032 (USD MILLION) 76
TABLE 15 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR URINE, BY REGION, 2019–2032 (USD MILLION) 77
TABLE 16 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 77
TABLE 17 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 80
TABLE 18 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR TESTOSTERONE TEST, BY REGION, 2019–2032 (USD MILLION) 81
TABLE 19 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ESTRADIOL TEST, BY REGION, 2019–2032 (USD MILLION) 81
TABLE 20 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ANTI-MÜLLERIAN HORMONE TEST, BY REGION, 2019–2032 (USD MILLION) 82
TABLE 21 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PROLACTIN TEST, BY REGION, 2019–2032 (USD MILLION) 82
TABLE 22 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PROGESTERONE TEST, BY REGION, 2019–2032 (USD MILLION) 83
TABLE 23 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FOLLICLE-STIMULATING HORMONE TEST, BY REGION, 2019–2032 (USD MILLION) 83
TABLE 24 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR LUTEINIZING HORMONE TEST, BY REGION, 2019–2032 (USD MILLION) 84
TABLE 25 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR Β-HCG TEST, BY REGION, 2019–2032 (USD MILLION) 84
TABLE 26 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 85
TABLE 27 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 87
TABLE 28 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR COLLOIDAL GOLD LATERAL FLOW ASSAYS, BY REGION, 2019–2032 (USD MILLION) 88
TABLE 29 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2019–2032 (USD MILLION) 89
TABLE 30 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR LAB-ON-A-CHIP, BY REGION, 2019–2032 (USD MILLION) 89
TABLE 31 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 90
TABLE 32 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 94
TABLE 33 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GESTATIONAL DIABETES, BY REGION, 2019–2032 (USD MILLION) 95
TABLE 34 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR VAGINAL INFECTION, BY REGION, 2019–2032 (USD MILLION) 96
TABLE 35 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR URINARY TRACT INFECTION, BY REGION, 2019–2032 (USD MILLION) 96
TABLE 36 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS, BY REGION, 2019–2032 (USD MILLION) 97
TABLE 37 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HEMOGLOBIN DEFICIENCY, BY REGION, 2019–2032 (USD MILLION) 97
TABLE 38 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR BREAST CANCER, BY REGION, 2019–2032 (USD MILLION) 98
TABLE 39 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR THYROID DISEASE, BY REGION, 2019–2032 (USD MILLION) 98
TABLE 40 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2019–2032 (USD MILLION) 99
TABLE 41 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 99
TABLE 42 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CHLAMYDIA, BY REGION, 2019–2032 (USD MILLION) 100
TABLE 43 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GONORRHEA, BY REGION, 2019–2032 (USD MILLION) 100
TABLE 44 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HIV, BY REGION, 2019–2032 (USD MILLION) 101
TABLE 45 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SYPHILIS, BY REGION, 2019–2032 (USD MILLION) 101
TABLE 46 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 102
TABLE 47 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY REGION, 2019–2032 (USD MILLION) 102
TABLE 48 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 103
TABLE 49 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR POLYCYSTIC OVARY SYNDROME, BY REGION, 2019–2032 (USD MILLION) 103
TABLE 50 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OVULATION DISORDERS, BY REGION, 2019–2032 (USD MILLION) 104
TABLE 51 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 104
TABLE 52 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PREGNANCY TESTING, BY REGION, 2019–2032 (USD MILLION) 105
TABLE 53 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 105
TABLE 54 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 107
TABLE 55 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY REGION, 2019–2032 (USD MILLION) 108
TABLE 56 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 109
TABLE 57 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2032 (USD MILLION) 109
TABLE 58 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2032 (USD MILLION) 110
TABLE 59 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HYPERMARKET/SUPERMARKET, BY REGION, 2019–2032 (USD MILLION) 110
TABLE 60 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY REGION, 2019–2032 (USD MILLION) 111
TABLE 61 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 111
TABLE 62 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR E-COMMERCE PLATFORMS, BY REGION, 2019–2032 (USD MILLION) 112
TABLE 63 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2032 (USD MILLION) 112
TABLE 64 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 114
TABLE 65 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOSPITALS, BY REGION, 2019–2032 (USD MILLION) 115
TABLE 66 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2032 (USD MILLION) 116
TABLE 67 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOME SETTINGS, BY REGION, 2019–2032 (USD MILLION) 116
TABLE 68 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 117
TABLE 69 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2019–2032 (USD MILLION) 119
TABLE 70 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 121
TABLE 71 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 122
TABLE 72 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 123
TABLE 73 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 123
TABLE 74 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 124
TABLE 75 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 125
TABLE 76 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 125
TABLE 77 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 126
TABLE 78 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 126
TABLE 79 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 126
TABLE 80 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 127
TABLE 81 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 127
TABLE 82 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 127
TABLE 83 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 128
TABLE 84 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 128
TABLE 85 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 128
TABLE 86 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 129
TABLE 87 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 129
TABLE 88 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 130
TABLE 89 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 130
TABLE 90 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 131
TABLE 91 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 131
TABLE 92 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 131
TABLE 93 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 132
TABLE 94 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 132
TABLE 95 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 132
TABLE 96 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 133
TABLE 97 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 133
TABLE 98 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 134
TABLE 99 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 134
TABLE 100 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 135
TABLE 101 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 135
TABLE 102 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 136
TABLE 103 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 136
TABLE 104 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 136
TABLE 105 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 137
TABLE 106 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 137
TABLE 107 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 137
TABLE 108 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 138
TABLE 109 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 138
TABLE 110 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 139
TABLE 111 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 139
TABLE 112 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 140
TABLE 113 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 140
TABLE 114 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 141
TABLE 115 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 141
TABLE 116 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 141
TABLE 117 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 142
TABLE 118 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 142
TABLE 119 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 145
TABLE 120 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 146
TABLE 121 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 146
TABLE 122 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 146
TABLE 123 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 147
TABLE 124 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 147
TABLE 125 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 148
TABLE 126 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 148
TABLE 127 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 149
TABLE 128 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 149
TABLE 129 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 149
TABLE 130 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 150
TABLE 131 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 150
TABLE 132 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 151
TABLE 133 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 151
TABLE 134 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 151
TABLE 135 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 152
TABLE 136 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 152
TABLE 137 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 153
TABLE 138 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 153
TABLE 139 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 154
TABLE 140 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 154
TABLE 141 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 154
TABLE 142 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 155
TABLE 143 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 155
TABLE 144 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 155
TABLE 145 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 156
TABLE 146 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 156
TABLE 147 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 157
TABLE 148 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 157
TABLE 149 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 158
TABLE 150 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 158
TABLE 151 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 159
TABLE 152 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 159
TABLE 153 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 159
TABLE 154 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 160
TABLE 155 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 160
TABLE 156 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 160
TABLE 157 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 161
TABLE 158 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 161
TABLE 159 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 162
TABLE 160 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 162
TABLE 161 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 163
TABLE 162 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 163
TABLE 163 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 164
TABLE 164 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 164
TABLE 165 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 164
TABLE 166 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 165
TABLE 167 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 165
TABLE 168 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 165
TABLE 169 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 166
TABLE 170 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 166
TABLE 171 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 167
TABLE 172 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 167
TABLE 173 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 168
TABLE 174 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 168
TABLE 175 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 169
TABLE 176 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 169
TABLE 177 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 169
TABLE 178 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 170
TABLE 179 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 170
TABLE 180 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 170
TABLE 181 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 171
TABLE 182 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 171
TABLE 183 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 172
TABLE 184 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 172
TABLE 185 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 173
TABLE 186 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 173
TABLE 187 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 174
TABLE 188 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 174
TABLE 189 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 174
TABLE 190 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 175
TABLE 191 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 175
TABLE 192 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 175
TABLE 193 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (USD MILLION) 176
TABLE 194 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 176
TABLE 195 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 177
TABLE 196 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 177
TABLE 197 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 178
TABLE 198 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 178
TABLE 199 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 179
TABLE 200 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 179
TABLE 201 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 179
TABLE 202 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 180
TABLE 203 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 180
TABLE 204 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 182
TABLE 205 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 183
TABLE 206 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 184
TABLE 207 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 184
TABLE 208 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 185
TABLE 209 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 185
TABLE 210 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 186
TABLE 211 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 186
TABLE 212 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 187
TABLE 213 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 187
TABLE 214 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 187
TABLE 215 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 188
TABLE 216 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 188
TABLE 217 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 189
TABLE 218 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 189
TABLE 219 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 190
TABLE 220 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 190
TABLE 221 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 191
TABLE 222 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 191
TABLE 223 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 192
TABLE 224 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 192
TABLE 225 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 192
TABLE 226 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 193
TABLE 227 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 193
TABLE 228 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 193
TABLE 229 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 194
TABLE 230 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 194
TABLE 231 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 195
TABLE 232 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 195
TABLE 233 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 196
TABLE 234 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 196
TABLE 235 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 197
TABLE 236 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 197
TABLE 237 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 197
TABLE 238 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 198
TABLE 239 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 198
TABLE 240 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 198
TABLE 241 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 199
TABLE 242 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 199
TABLE 243 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 199
TABLE 244 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 200
TABLE 245 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 200
TABLE 246 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 201
TABLE 247 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 201
TABLE 248 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 202
TABLE 249 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 202
TABLE 250 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 202
TABLE 251 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 203
TABLE 252 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 203
TABLE 253 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 204
TABLE 254 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 204
TABLE 255 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 205
TABLE 256 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 205
TABLE 257 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 206
TABLE 258 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 206
TABLE 259 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 207
TABLE 260 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 207
TABLE 261 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 207
TABLE 262 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 208
TABLE 263 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 208
TABLE 264 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 208
TABLE 265 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 209
TABLE 266 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 209
TABLE 267 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 210
TABLE 268 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 210
TABLE 269 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 211
TABLE 270 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 211
TABLE 271 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION) 212
TABLE 272 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019–2032 (USD MILLION) 212
TABLE 273 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 212
TABLE 274 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019–2032 (USD MILLION) 213
TABLE 275 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019–2032 (USD MILLION) 213
TABLE 276 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019–2032 (USD MILLION) 213
TABLE 277 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 214
TABLE 278 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019–2032 (USD MILLION) 215
TABLE 279 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019–2032 (METRIC TON) 216
TABLE 280 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019–2032 (USD MILLION) 216
TABLE 281 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 217
TABLE 282 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019–2032 (USD MILLION) 217
TABLE 283 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 218
TABLE 284 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2032 (USD MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET: STRUCTURE 34
FIGURE 2 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 50
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032) 53
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2032) 54
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET 56
FIGURE 6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2023 & 2032 (USD MILLION) 66
FIGURE 7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY PRODUCT, 2023 67
FIGURE 8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2023 & 2032 (USD MILLION) 70
FIGURE 9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY AGE, 2023 71
FIGURE 10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2023 & 2032 (USD MILLION) 74
FIGURE 11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY SAMPLE TYPE, 2023 75
FIGURE 12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2023 & 2032 (USD MILLION) 79
FIGURE 13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY TEST TYPE, 2023 80
FIGURE 14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2023 & 2032 (USD MILLION) 87
FIGURE 15 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY TECHNOLOGY, 2023 88
FIGURE 16 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION) 93
FIGURE 17 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY APPLICATION, 2023 95
FIGURE 18 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 107
FIGURE 19 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 108
FIGURE 20 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2023 & 2032 (USD MILLION) 114
FIGURE 21 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY END USER, 2023 115
FIGURE 22 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2023 & 2032 (USD MILLION) 118
FIGURE 23 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY REGION, 2023 119
FIGURE 24 NORTH AMERICA MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION) 120
FIGURE 25 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 121
FIGURE 26 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY COUNTRY, 2023 122
FIGURE 27 EUROPE MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION) 143
FIGURE 28 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 144
FIGURE 29 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY COUNTRY, 2023 145
FIGURE 30 ASIA-PACIFIC MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION) 181
FIGURE 31 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 182
FIGURE 32 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%) 183
FIGURE 33 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 214
FIGURE 34 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%) 215
FIGURE 35 REST OF THE WORLD MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION) 262
FIGURE 36 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 263
FIGURE 37 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%) 264
FIGURE 38 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 275
FIGURE 39 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%) 276
FIGURE 40 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 302
FIGURE 41 COMPETITOR DASHBOARD: GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET 303
FIGURE 42 SWISS PRECISION DIAGNOSTICS GMBH: SWOT ANALYSIS 311
FIGURE 43 WONDFO: SWOT ANALYSIS 316
FIGURE 44 CHURCH & DWIGHT CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 319
FIGURE 45 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS 321
FIGURE 46 SEKISUI DIAGNOSTICS: SWOT ANALYSIS 331
FIGURE 47 COFOE MEDICAL TECHNOLOGY CO., LTD.: SWOT ANALYSIS 339
FIGURE 48 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.: SWOT ANALYSIS 345
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們